Gaudium IVF and Women Health Limited has dispatched the notice for its 11th Annual General Meeting, scheduled for Monday, September 28, 2026. The meeting will be held via Video Conferencing or Other Audio Visual Means.

The company sent the notice and the Annual Report for FY26 electronically on Thursday, September 3, 2026, to members with registered email addresses. This update supersedes the earlier pre-AGM newspaper notice published on September 1, 2026.

Dispatch Details

Members without registered email addresses received physical letters containing a web link and navigation path to access the complete Annual Report, in compliance with Regulation 36(1)(b) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The deemed venue for the meeting remains the registered office in New Delhi. The cut-off date for reckoning voting rights is Monday, September 21, 2026.

Voting Process

National Securities Depository Limited facilitates e-voting for all resolutions. Remote e-voting commenced on Friday, September 25, 2026, at 9:00 am and closes on Sunday, September 27, 2026, at 5:00 pm.

Shareholders holding shares as of the cut-off date are eligible to vote. Detailed instructions for joining the virtual session and casting votes are included in the formal AGM notice available via the provided web link.

Gaudium IVF & Women Health reported a significant moderation in profitability for the first quarter of FY27, with consolidated net profit from continuing operations falling 42% year-on-year to ₹177.59 lakh. The decline was largely attributed to strategic investments in expansion and technology, including a one-time marketing cost of ₹253.24 lakh for its AI-led embryology tools, SiD and ERICA.

Despite the profit dip, the company’s top line expanded. Consolidated revenue from operations rose 9.13% YoY to ₹1,937.66 lakh, up from ₹1,775.59 lakh in the corresponding period of FY26. However, EBITDA (excluding other income) contracted sharply by 52.96% to ₹242.40 lakh, reflecting the heavy upfront spending required for new infrastructure.

Financial Performance Overview

The standalone figures mirrored the consolidated trend, with net profit declining 29.24% YoY to ₹166.35 lakh. Standalone revenue increased modestly by 11.44% to ₹1,367.73 lakh. The company highlighted that these costs are part of a planned rollout for FY27, aimed at scaling its pan-India presence.

What the Numbers Show

The divergence between revenue growth and profit contraction highlights the aggressive capital deployment phase Gaudium is currently undertaking. While revenue grew nearly 10%, the one-time marketing spend alone (₹253.24 lakh) exceeded the entire consolidated net profit for the quarter (₹177.59 lakh). This indicates that the bottom-line pressure is non-operational in nature, driven by specific growth investments rather than a deterioration in core clinical margins. Adjusted EBITDA, excluding this one-time cost, stood at ₹532.75 lakh, implying an adjusted margin of 27.49%, which remains robust compared to the reported 12.51% margin.

Expansion and Strategic Initiatives

Gaudium attributed the margin compression to front-loading expenses associated with its rapid growth strategy. Key drivers included:

• Pre-operationalisation spends at the new Delhi South Extension Hub.
• Preparatory expenses for upcoming hubs in Nagpur and Gurugram.
• Incremental hiring of clinical talent.
• Integration of AI-powered tools SiD and ERICA across centres.

The company currently operates 8 hubs and 28 spokes across nine states. It claims a first-attempt success rate of 62%, which it states has seen an 8–9% increase with the adoption of its AI tools. With an average revenue per patient of ₹3.5 lakh, the focus remains on scaling volume through wider geographic access and technological differentiation.

Looking ahead, management indicated that these investments are expected to support revenue growth as the new centres scale up in subsequent quarters. The company maintains its pan-India footprint strategy, aiming to leverage regulatory compliance and brand trust as entry barriers against competitors.